Parker E F, Marks R D, Kratz J M, Chaikhouni A, Warren E T, Bartles D M
Ann Thorac Surg. 1985 Aug;40(2):121-5. doi: 10.1016/s0003-4975(10)60003-3.
The purpose of this report is to record the results of a treatment protocol for patients with carcinoma of the esophagus. In May, 1980, we initiated a program of chemoradiation therapy preliminary to resection in patients in whom the protocol was applicable. The chemotherapy consisted of mitomycin-C, 10 mg as a bolus intravenous injection on day 1, and 5-fluorouracil, 1,000 mg per square meter of body surface area in 1,000 ml of 5% glucose solution in distilled water given intravenously on each of days 1 through 4. The radiation therapy consisted of 3,000 rads in three weeks using cobalt 60 or 6 MeV or greater, with ports to cover the tumor and mediastinum. This protocol was given to patients with primary carcinoma of the esophagus whose disease remained or became operable during or following the course of the chemoradiation. Among the patients treated according to the protocol, the operability rate was increased. The resectability rate remained about the same as in our previous experience. The operative mortality was lessened appreciably. The percentage of resected specimens of the esophagus showing residual tumor decreased. However, the absence of any residual tumor in the surgical specimen has not conferred any improved chance of long-term survival to date. There has been a two-year survival of 33% (7/21) among the small group having chemoradiation therapy prior to resection, and this figure is roughly the same as that in our previously reported series of patients treated by preoperative irradiation (4,500 rads in three weeks) and resection without the chemotherapeutic adjunct.(ABSTRACT TRUNCATED AT 250 WORDS)
本报告旨在记录食管癌患者治疗方案的结果。1980年5月,我们启动了一项适用于该方案患者的术前放化疗计划。化疗方案为:丝裂霉素-C,第1天静脉推注10mg;5-氟尿嘧啶,每平方米体表面积1000mg,加入1000ml 5%葡萄糖蒸馏水溶液中,于第1至4天每天静脉滴注。放射治疗采用钴60或6兆电子伏特及以上射线,三周内给予3000拉德,照射野覆盖肿瘤及纵隔。该方案应用于那些在放化疗期间或之后病情仍可手术或变为可手术的原发性食管癌患者。在按照该方案治疗的患者中,可手术率有所提高。切除率与我们之前的经验大致相同。手术死亡率明显降低。食管切除标本中显示残留肿瘤的比例下降。然而,迄今为止,手术标本中无任何残留肿瘤并未带来长期生存机会的改善。在术前接受放化疗的一小部分患者中,两年生存率为33%(7/21),这一数字与我们之前报道的术前接受三周4500拉德照射及手术切除但未加化疗辅助治疗的患者系列大致相同。(摘要截选至250字)